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Abstract: The inflammatory response at infliximab (IFX) treatment
failure due to tumor necrosis factor (TNF)-a-independent Crohn disease
activity is unknown.
This is an exploratory, hypothesis-generating study based on
samples collected in a clinical trial among patients failing conventional
IFX dosages and treated with an intensified IFX regimen for 12 weeks.
Patients with clinical response at week 12, as defined by a reduction of
Crohn disease activity index by 70, were considered to suffer from
nonimmune pharmacokinetic (PK) treatment failure (n¼ 18), and non-
responders had a presumed pharmacodynamic (PD) failure due to non-
TNF-driven disease (n¼ 8). Patients failing IFX due to functional anti-
IFX antibodies (n¼ 2) were excluded. The study population also
comprised a group of 12 patients in long-term remission on IFX. A
functional cell-based reporter gene assay was applied to measure IFX
and anti-IFX antibodies. Circulating cytokines and cytokine receptors
were assessed by enzyme-linked immunosorbent assay: granulocyte-
macrophage colony-stimulating factor, interferon-g, interleukin (IL)-
1a, IL-1b, IL-1Ra, IL-6, IL-10, IL-12p70, soluble TNF receptor (sTNF-
R) 1, sTNF-R2, IL-17A, and monocyte chemotactic protein 1.
The IFX levels were similar between patients with IFX failure
caused by nonimmune PK or PD at treatment failure (median 1.4 vsMD, PhD, DMSc, MD, DMSc,
n, MD, DMSc
signaling pathways in their disease. Cytokine and cytokine receptor
levels were comparable between patients with nonimmune PK failure
and PD failure at time of manifestation of IFX failure, but with higher
IL-6 and sTNF-R2 levels among IFX treatment failures as compared
with patients in remission (IL-6 median 3.6 vs <3.1 pg/mL; P¼ 0.03;
sTNF-R2 3207 vs 2547pg/mL; P¼ 0.01). IL-6 and sTNF-R2 were lower
after 12weeks in nonimmunePK failures than in PD failures (<3.1 vs 4.0;
P¼ 0.02; 3209 vs 4740; P¼ 0.04, respectively), and were measured at
levels comparable with patients in remission. Further, trends of decreased
IL-6 and sTNF-R2 levels among nonimmune PK failures during IFX
intensification (P< 0.05 and P¼ 0.12) were observed.
These observations indicate that IL-6 and sTNF-R2 are of potential
relevance in driving the inflammatory response in IFX refractory Crohn
disease caused by TNF-a-independent disease activity.
(Medicine 95(16):e3417)
Abbreviations: Abs = antibodies, CDAI = Crohn Disease Activity
Index, ELISA = enzyme-linked immunosorbent assay, GM-CSF =
granulocyte-macrophage colony-stimulating factor, IFN =
interferon, IFX = infliximab, IL = interleukin, IQR = interquartile
range, LLOQ = lower limit of quantification, MCP-1 = monocyte
chemotactic protein 1, PD = pharmacodynamic, PK =
pharmacokinetic, q = frequency of IFX dosing in weeks, ra =
receptor antagonist, RGA = reporter gene assay, SES-CD = Simple
Endoscopic Score for Crohn disease, sTNF-R = soluble TNF
receptor, TNF = tumor necrosis factor.
INTRODUCTION
A ntitumor necrosis factor (TNF)-a therapy with infliximab(IFX) is effective for management of patients with Crohn
disease refractory to conventional immunomodulating thera-
pies.1 Regrettably, approximately half of the patients lose effect
of IFX therapy over time.2 The underlying mechanisms for IFX
treatment failure and their corresponding interventions can be
identified by measurements of circulating levels of trough IFX
and anti-IFX antibodies (Abs) according to the algorithm out-
lined in Figure 1.3 Treatment strategy according to this algor-
ithm has become an integrated part of clinical practice because
it results in comparable or superior clinical outcomes at reduced
costs as compared with intensification of the IFX treatment
regimen.4–11
Treatment failure caused by a pharmacokinetic (PK) pro-
blem is characterized by insufficient IFX bioavailability to
adequately suppress TNF-a-mediated inflammatory disease
activity.3,12 This can originate as a consequence of immunogeni-
citywith formation of functional anti-IFXAbs that neutralize IFX
and/or increase drug clearance (Figure 1: upper left row)13;of nonimmune-mediated mechanisms
a heavy inflammatory load leading to
ure 1: upper right row).14–16 Treatment
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cells, hemoglobin, and albumin), endoscopic remission (Simple
Endoscopic Score for Crohn disease [SES-CD] 1), and deep
remission (histologically inactive disease) (Figure 2).
FIGURE 1. Personalized treatment strategy at anti-TNF treatment
failure. Algorithm based on measurements of anti-TNF drug levels
and antidrug antibodies (Abs) for identification of underlying
mechanisms for anti-TNF treatment failure with, for example,
infliximab (IFX) and corresponding interventions. Initially devised
by our group,3 and later tested in clinical trials and observational
4,5,7–10 3
FIGURE 2. Study flow. The study population consisted of Crohn
Steenholdt et alfailure caused by a PK problem should preferably restore suffi-
cient inhibition of TNF-a. This is characteristically done by
intensification of the IFX regimen if anti-IFX Abs are absent,
or by switching to a different TNF-inhibitor if anti-IFX Abs are
present.3–10,12
During IFX therapy, a notable proportion of patients
experiences relapse of their Crohn disease because of a phar-
macodynamic (PD) problem (Figure 1: lower rows).7,10 This
condition originates from predominantly or exclusively non-
TNF-driven inflammatory disease pathways—either primarily
or as a result of redundancy with a dynamic shift during ongoing
IFX therapy.3,12,17,18 It is characterized by relatively high
circulating levels of IFX at time of manifestation of failure,
and lack of effect of IFX dose intensification.4,7,9,10,19,20 Con-
tinued anti-TNF therapy is inefficient in such cases.3,4,7–10,12,20
Identification of mediators maintaining active TNF-a-indepen-
dent disease may uncover rational treatment targets for future
biologic agents, but the inflammatory response in these patients
is yet unaccounted for.14,21–27
METHODS
studies. Adapted from the studies by Bendtzen et al and
Steenholdt et al.7 Reproduced andmodified with permission from
BMJ Publishing Group Ltd from the study by Steenholdt et al.
TNF¼ tumor necrosis factor.Objectives
The aim of this study was to explore selected character-
istics of the systemic inflammatory response in patients with
2 | www.md-journal.comCrohn disease failing IFX due to a PD or a nonimmune PK
problem as compared with patients in remission on IFX.
Furthermore, to compare characteristics in patients’ refractory
to intensified IFX due to PD treatment failure with those of
patients failing IFX due to nonimmune PK.
Study Design and Patients
This was a hypothesis-generating and explorative study
which was based on data and samples obtained as part of a
randomized controlled trial in which Crohn’s disease patients
with loss of response of IFX maintenance therapy (Crohn
Disease Activity Index [CDAI]220 or minimum one draining
perianal fistula) had been randomized to an intensified IFX
regimen or to personalized therapy based on IFX and anti-IFX
Abs levels at time of treatment failure as outlined in Figure 1
and detailed in references.7,8 The current study population
comprised patients who had received an intensified IFX regi-
men throughout the entire 12-week study period (5mg/kg every
[q] 4 weeks, n¼ 22; q >4, n¼ 4), and with blood samples
available both at baseline corresponding time of treatment
failure (week 0) and also at end of trial (week 12)
(Figure 2). Patients with treatment failure caused by fistulizing
Crohn disease only were excluded along with patients who had
been dose-intensified on IFX in the presence of functionally
active anti-IFX Abs (Figure 1: upper left row). Clinical response
after 12 weeks of intensified IFX therapy was defined by 70
point reduction of CDAI from baseline. Patients without
response were considered to suffer from IFX failure character-
ized by non-TNF-a-driven disease pathways, that is, PD failure
(Figure 1: lower rows). Responders were considered to suffer
from IFX failure due to a nonimmune-mediated PK problem
characterized by a TNF-a-driven disease activity (Figure 1:
upper right row).
The study population also included a cohort of patients
with luminal Crohn disease (n¼ 12) treated with IFX for
minimum 1 year, and in clinical remission (CDAI <150),
biochemical remission (normal values of CRP, white blood
Medicine  Volume 95, Number 16, April 2016disease patients with infliximab (IFX) treatment failure due to a
pharmacodynamic (PD) problem or a nonimmune pharmacoki-
netic (PK) problem. In addition, a cohort of patients in remission
on IFX was included.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
The study was approved by the Danish Medicines Agency
(EudraCT 2009–009926–94; 2012–002702–51), the Danish
regional ethics committees (HA-2009–009; H-4–2012–099),
and the Danish Data Protection Agency (2007–58–0015;
750.89–27), and was registered at ClinicalTrials.gov
(NCT00851565; NCT01817426). Informed oral and written
consent was obtained from all patients.
Blood Samples
Blood samples were collected as trough levels. Serum and
plasma were collected after centrifugation of 10mL venous
blood (5minutes at 3500 rpm), and stored at 808C. All
analyses were performed under blinded conditions.
Analyses of IFX and Anti-IFX Abs Concentrations
Serum samples were analyzed for concentrations of IFX
and anti-IFX Abs by a functional cell-based reporter gene assay
(RGA) (Eurodiagnostica, Malmo¨, Sweden).
Cytokine Assessments
Plasma levels of interleukin (IL)-6 were measured by
enzyme-linked immunosorbent assay (ELISA) according to
the manufacturer’s instructions (R&D Systems, Minneapolis,
MN) (lower limit of quantification [LLOQ] 3.1 pg/mL). Plasma
levels of the following cytokines were examined by Bio-Plex Pro
Human Inflammation multiplex ELISA: IFN (interferon)-g
(LLOQ 6.3 pg/mL), IL-10 (1.7 pg/mL), IL-12 p70 (1.3 pg/mL),
soluble TNF receptor 1 (sTNF-R1) (26.8 pg/mL), and sTNF-R2
(30.3 pg/mL), and by Bio-Pex Pro Human group I multiplex
Medicine  Volume 95, Number 16, April 2016ELISA: granulocyte-macrophage colony-stimulating factor
(GM-CSF) (63.3 pg/mL), IL-1a (1.4 pg/mL), IL-1b (3.2 pg/
mL), IL-1 receptor antagonist (Ra) (81.1 pg/mL), IL-17A
TABLE 1. Patient Characteristics
Study
of IFX F
Male sex, no. (%) 8
Age at diagnosis, year median (IQR) 24
BMI, median (IQR) 26
Smoking, no. (%) 8
Localization of luminal disease
Colon only, no. (%) 9
Small bowel only, no. (%) 2
Colon and small bowel, no. (%) 5
Colon and ileocoecal, no. (%) 8
Limited ileocoecal, no. (%) 2
Extraintestinal manifestations, no. (%) 16
Previous segmental resection, no. (%)
Concomitant immunosuppressives, no. (%) 12
Systemic corticosteroids or budesonide, no. (%) 1
Disease duration at IFX initiation, year median (IQR) 7
IFX infusions, median (IQR) 7
IFX treatment duration, days, median (IQR) 405
CDAI, median (IQR) 276
CRP, mg/mL median (IQR) 3
White blood cells, 109/L median (IQR) 7.3
Hemoglobin, g/dL median (IQR) 13.4
Albumin, g/L median (IQR) 41
BMI¼ body mass index, CDAI¼Crohn Disease Activity Index, IFX¼
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.(4.9 pg/mL), and monocyte chemotactic protein 1 (MCP-1)
(2.1 pg/mL). Cytokines assessed in the study were selected based
on of their putative involvement in the processes underlying
inflammatory bowel disease (IBD).14,21–28 All measurements
were performed in duplicate and with coefficient of variations
<20%. Concentrations were given in pg/mL and with 1 decimal
in case of a very high sensitivity (LLOQ <10 pg/mL).
Statistics
Descriptive statistics were given as percentages for discrete
variables, and as median with interquartile range (IQR) for
continuous variables. Comparisons of patient characteristics
were done by Fisher exact test or chi-square test (discrete
variables), or by Mann–Whitney U test (continuous variables).
Comparisons of systemic cytokine expression in patients with
IFX treatment failure and in remission on IFX were done by
Mann–Whitney U test. Comparisons of cytokine levels, and
IFX levels, in patients with PD or nonimmune PK failure at
baseline and week 12 were done by Mann–Whitney U test, and
changes across time in each subgroup were evaluated by
Wilcoxon signed-rank test. Values below LLOQ were con-
sidered to be null. Statistical analyses were done in SPSS
version 22 (IBM, Somer, NY). Two-sided P values <0.05 were
considered statistically significant.
RESULTS
Study Population
The study population comprised patients in remission on
IFX, and also patients with IFX treatment failure due to pre-
Pharmacodynamic IFX Treatment Failuresumed PD or nonimmune PK issues (Figure 2). As shown in
Table 1, characteristics of included patients reflected the differ-
ent clinical response types to IFX therapy.
Population
ailures (n¼ 26)
Study Population
of IFX Remission (n¼ 12) P
(31) 7 (58) 0.16
(19–32) 35 (26–48) 0.04
(22–28) 28 (25–29) 0.22
(31) 2 (17) 0.45
(35) 4 (33) 0.87
(8) 0 (0)
(19) 2 (17)
(31) 5 (42)
(8) 1 (8)
(62) 1 (8) <0.01
(519) 2 (17) 1.00
(46) 7 (58) 0.73
(4) 0 (0) 1.00
(2–12) 7 (3–10) 0.89
(5–16) 14 (10–20) 0.02
(165–822) 707 (502–967) 0.02
(240–329) 51 (27–88) <0.001
(0–18) 0 (0–3) 0.03
(6.5–9.0) 5.9 (4.2–6.9) 0.01
(12.6–14.2) 14.7 (13.9–15.3) <0.01
(38–43) 45 (43–45) <0.01
infliximab, IQR¼ interquartile range.
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TABLE 2. Systemic Inflammatory Response at IFX Treatment Failure
Study Population of IFX Failures (n¼ 26) Study Population of IFX Remission (n¼ 12) P
IL-6 3.6 (<3.1–6.2) <3.1 (<3.1–<3.1) 0.03
MCP-1 <2.1 (<2.1–17.5) 4.9 (<2.1–38.9) 0.39
sTNF-R1 1073 (817–1372) 936 (817–1213) 0.55
rot
Steenholdt et al Medicine  Volume 95, Number 16, April 2016Cytokine and Cytokine Receptor Levels at IFX
Treatment Failure
As detailed in Table 2, circulating levels of IL-6 and sTNF-
R2 were significantly higher at the time of IFX treatment failure
as compared with levels in patients on IFX with quiescent
disease. Levels of sTNF-R1 and MCP-1 were not significantly
different between patients with IFX failure and those with an
IFX-induced remission. The remaining cytokines and cytokine
receptors assessed were generally below LLOQ (not shown).
Inflammatory Characteristics at PD and
Nonimmune PK IFX Treatment Failure
Characteristics of patients with IFX treatment failure due
to PD or nonimmune PK are shown in Table 3. Circulating anti-
TNF activities in these subgroups at treatment failure were
sTNF-R2 3207 (2637–5358)
IFX¼ infliximab, IL¼ interleukin, MCP-1¼monocyte chemotactic pmedian 1.4 versus 2.4mg/mL (P¼ 0.52); after 12 weeks of
intensified IFX regimen 8.8 versus 7.7 (P¼ 0.93); and the
increase in anti-TNF activity during the 12-week period of
TABLE 3. Characteristics of the Study Population According to M
Male sex, no. (%)
Age at diagnosis, year median (IQR)
BMI, median (IQR)
Smoking, no. (%)
Localization of luminal disease
Colon only, no. (%)
Small bowel only, no. (%)
Colon and small bowel, no. (%)
Colon and ileocoecal, no. (%)
Limited ileocoecal, no. (%)
Extraintestinal manifestations, no. (%)
Previous segmental resection, no. (%)
Concomitant immunosuppressives, no. (%)
Systemic corticosteroids or budesonide, no. (%)
Disease duration at IFX initiation, year median (IQR)
IFX infusions, median (IQR)
IFX treatment duration, days, median (IQR)
CDAI, median (IQR)
CRP protein at IFX failure, mg/mL median (IQR)
CRP decrease during IFX intensification, mg/mL median (IQR)
White blood cells, 109/L median (IQR)
Hemoglobin, g/dL median (IQR)
Albumin, g/L median (IQR)
BMI¼ body mass index, CDAI¼Crohn disease activity index, IFX¼
pharmacokinetic.
4 | www.md-journal.comtreatment intensification was 8.1 versus 5.6 (P¼ 0.85)
(Figure 3).
As shown in Table 4, cytokine levels did not differ
significantly between patients with IFX treatment failure due
to PD or nonimmune PK at time of manifestation of IFX
treatment failure. However, IL-6 levels decreased significantly
during intensification of IFX treatment in individual patients
with nonimmune PK failure, but not in those with PD failure
(Table 4 and Figure 4). Furthermore, IL-6 and sTNF-R2 levels
were significantly lower after 12 weeks of treatment in patients
with nonimmune PK failure (Table 4), and at levels comparable
with those in patients in remission on IFX (IL-6: <3.1 vs
<3.1 pg/mL; P¼ 0.85; sTNF-R2: 3209 vs 2547 pg/mL;
P¼ 0.19) (Table 2).
Assessment of conditions for IL-6 in patients with detect-
able IL-6 at baseline only revealed comparable findings to the
2547 (1977–2889) 0.01
ein 1, sTNF-R¼ soluble tumor necrosis factor receptor.above: baseline IL-6 levels were not significantly different
between nonimmune PK or PD IFX failures (median 6.2 vs
4.8 pg/mL; P¼ 0.72), IL-6 decreased significantly solely in
echanism for IFX Failure
Nonimmune PK IFX
Failure (n¼ 18)
PD IFX
Failure (n¼ 8) P
5 (28) 3 (38) 0.67
26 (20–36) 21 (17–26) 0.08
25 (22–28) 26 (21–29) 0.89
6 (33) 2 (25) 1.00
9 (50) 0 (0) 0.06
1 (6) 1 (13)
3 (17) 2 (25)
5 (28) 3 (38)
0 (0) 2 (25)
11 (61) 5 (63) 1.00
2 (11) 3 (38) 0.28
9 (50) 3 (38) 0.68
0 (0) 1 (13) 0.31
6 (2–12) 9 (3–12) 0.53
6 (5–11) 16 (6–19) 0.18
300 (208–564) 866 (301–1097) 0.12
306 (245–341) 242 (233–285) 0.09
3 (0–15) 8 (0–19) 0.71
2 (0-13 1 (-5–12) 0.48
7.5 (6.9–9.5) 6.7 (5.8–8.3) 0.22
13.4 (12.6–14.3) 13.1 (12.3–13.8) 0.51
41 (39–43) 41 (34–43) 0.44
infliximab, IQR¼ interquartile range, PD¼ pharmacodynamic, PK¼
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 3. Infliximab levels. Circulating infliximab (IFX) trough
levels measured by functional reporter gene assay (RGA) in
patients with IFX treatment failure due to nonimmune pharma-
Medicine  Volume 95, Number 16, April 2016individual patients with nonimmune PK failure (P< 0.01 and
P¼ 0.69, respectively), and IL-6 levels were significantly lower
after 12 weeks in patients with nonimmune PK failure (<3.1 vs
4.5 pg/mL; P< 0.05).
DISCUSSION
cokinetics (PK) (n¼18) or pharmacodynamics (PD) (n¼8) at time
of treatment failure (week 0) and after 12 weeks of intensified IFX
regimen.It is known that PK or PD mechanisms are involved in loss
of response to anti-TNF therapy as outlined in Figure 1.3,7,8,12,20
Although previous studies have focused mainly on PK reasons
TABLE 4. Systemic Inflammatory Response According to Mecha
Nonimmune PK IFX Failure (n¼ 18) PD IFX
Week 0 Week 12 Week 0
IL-6 <3.1 (<3.1–6.3) <3.1 (<3.1–3.1) 4.3 (<3.1–5.
MCP-1 <2.1 (<2.1–30.3) <2.1 (<2.1–48.0) <2.1 (<2.1–<
sTNF-R1 1055 (716–1426) 1109 (862–1292) 1110 (977–127
sTNF-R2 3202 (2558–4679) 3209 (2006–3934) 3462 (2669–84
IFX¼ infliximab, IL¼ interleukin, MCP-1¼monocyte chemotactic prote
tumor necrosis factor receptor.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.for anti-TNF treatment failure due to immunogenicity or non-
immune-mediated reasons for insufficient drug bioavailability,
this study, however, explored characteristics of the systemic
inflammatory response in patients with IFX treatment failure
presumably originating from an underlying PD problem in
which inhibition of TNF-a per se is ineffective.13,14 The main
findings of the present investigation are that a subgroup of
Crohn disease patients refractory to an intensified IFX regi-
men—presumably due to PD-related treatment failure—exhib-
ited a maintained detectable systemic expression of IL-6 during
the course of IFX intensification as opposed to patients with
nonimmune PK-related treatment failure, or patients in remis-
sion on IFX. Furthermore, sTNF-R2 levels were found to be
higher among patients with IFX failure as compared with those
with clinically quiescent disease, and generally higher at PD-
related treatment failure than at nonimmune PK failure. Taken
together, these observations indicate that patients with PD-
related IFX treatment failure exhibit a predominantly non-
TNF-a-mediated inflammatory disease phenotype that may
involve IL-6 and/or sTNF-R2.
Transcriptional data have suggested that anti-TNF therapy
associates with a diminished mucosal IL-6 expression among
primary anti-TNF nonresponsive Crohn disease patients.26 On
the contrary, as IL-6 was elevated before IFX intensification,
IL-6 may simply be a confounder due to unspecific inflamma-
tory activity.29 However, maintained expression of increased
circulating IL-6 in patients with ulcerative colitis and primary
IFX treatment failure supports involvement of IL-6 in TNF-a-
independent inflammation.27 Several studies have earlier pro-
posed IL-17A to be a central mediator of anti-TNF-a-indepen-
dent inflammation.24–26,28,30,31 Although IL-17A was below
LLOQ in the current study, involvement of IL-6, amongst other
cytokines, in the induction of a Th17 inflammatory response
might indicate that IL-6 plays a role in predominantly TNF-a-
independent inflammation among patients with a presumed PD-
related treatment failure. Hence, even though our data do not
provide direct evidence, they do, however, support the concept
that IL-6, the IL-6 receptor, or IL-6 intracellular signaling might
prove useful as therapeutic targets in the subgroup of patients
with IFX treatment failure characterized by an underlying PD
mechanism. Thus, clinical trials are obviously needed to assess
this hypothesis. Interestingly, a monoclonal Ab targeting the IL-
6 receptor was found effective for treatment of Crohn disease in
a pilot study.32–34 Furthermore, a recently published phase II
trial only available in abstract form reported significantly higher
Pharmacodynamic IFX Treatment Failureclinical response rates among Crohn disease patients with
previous anti-TNF treatment failure and treated with anti-IL-
6 monoclonal Ab (PF-0423921) than with placebo.35
nism for IFX Failure
Failure (n¼ 8)
P Week 0
Between Groups
P Week 12
Between GroupsWeek 12
9) 4.0 (<3.1–12.2) 0.43 0.02
2.1) <2.1 (<2.1–<2.1) 0.08 0.18
2) 1082 (893–1300) 0.53 0.94
03) 4740 (2904–5371) 0.37 0.04
in 1, PD¼ pharmacodynamic, PK¼ pharmacokinetic, sTNF-R¼ soluble
www.md-journal.com | 5
FIGURE 4. Interleukin (IL)-6 levels. Circulating IL-6 levels in
patients with infliximab (IFX) treatment failure due to nonimmune
pharmacokinetics (PK) (n¼18) or pharmacodynamics (PD)
(n¼8) at treatment failure (week 0) and after 12 weeks of
intensified IFX regimen. () P<0.05 by Wilcoxon signed-rank
test. Lower limit of IL-6 quantification (LLOQ) was 3.1pg/mL
Steenholdt et alOur findings concur with observations that outcome of IFX
therapy is associated with variations in the gene encoding TNF-
R2, and with reported characteristics of the mucosal gene
expression profile of TNF-R2 during ongoing IFX
therapy.23,36–38 Although it cannot be ruled out that maintained
elevated sTNF-R2 level observed in patients with PD-related
IFX treatment failure was a result of diminished TNF-a expres-
sion imposed by IFX intensification followed by a relative
increase in non-TNF-bound sTNF-R2, the corresponding con-
stant level of sTNF-R1 in both nonimmune PK and PD treat-
ment failures renders this unlikely. In contrast to the conditions
in Crohn disease, systemic sTNF-R2 levels are lower in patients
with active than inactive rheumatoid arthritis.39 Thus, it is
possible that the opposing trends in sTNF-R2 levels in active
versus quiescent Crohn disease and rheumatoid arthritis,
respectively, may contribute to observed differences in efficacy
of the sTNF-R2/human IgG construct, etanercept, in these
diseases.40,41
Several notable limitations of this study, however, need to
(dotted line), and values below LLOQ are arbitrarily set to
1.5pg/mL and shown as gray (n¼9 and n¼2, respectively).be attended. The sample size was restricted as relevant samples
were available only in some patients enrolled in an earlier
clinical trial.7,8 Further, the assessed cytokines and cytokine
6 | www.md-journal.comreceptors were selected based on their putative involvement in
IBD and did not cover all potentially involved inflammatory
mediators. Circulating IL-6 levels were only marginally higher
than LLOQ, and the inflammatory response was assessed in the
circulation where conditions may diverge from those of the
inflamed gut. As this was an exploratory study, correction for
multiple comparisons was not performed. Taken together, our
new observations described based on available knowledge of
IFX response in IBD are hypothesis-generating and need to be
validated in independent and larger cohorts.
It is currently impossible to discriminate between TNF-a
and non-TNF-a-driven pathways. It has been assumed that
patients refractory to IFX intensification, and without functional
anti-IFX Abs, had an underlying PD-related problem caused by
a non-TNF-a-driven disease, whereas responders had treatment
failure due to nonimmune PK problems because of TNF-a-
mediated disease activity.3,12,19 Although this was supported by
a similar anti-TNF activity in responders and nonresponders,
and a trend of more pronounced CRP decrease among respon-
ders than nonresponders, these patients with IBD might have
experienced treatment failure due to other reasons as well.20
This is rather crucial because lack of routine endoscopy to
verify inflammatory active disease at treatment failure intro-
duces a potential bias, that some patients may have entered the
trial without having genuine inflammatory loss of response, but
rather symptoms mimicking IFX treatment failure.42 Never-
theless, another research group has used a similar approach.26
Furthermore, exploratory analyses with exclusion of the
minority with undetectable IL-6 at time of manifestation of
treatment failure did not change our findings, but they actually
revealed more significant results. Assessment of IFX and anti-
IFX Abs by a high-sensitivity homogeneous mobility shift
binding assay revealed results coherent to those obtained by
the functional RGA primarily used here adding further support
to our findings.43 Finally, patients with functional anti-IFX Abs
present in the circulation at treatment failure were excluded
because the contribution of TNF-a in the inflammatory
response could not be defined based on the outcome of inten-
sified IFX treatments. Thus, anti-IFX Abs might a priory bias
this outcome. Although this is also a potential bias, only 2
patients had anti-IFX Abs, and an explorative inclusion of these
patients did not impose changes to our findings.
In conclusion, the present study indicates systemic altera-
tions of IL-6 and sTNF-R2 in Crohn disease refractory to IFX
caused by a TNF-a-independent disease pathway. If reproduced
Medicine  Volume 95, Number 16, April 2016and validated, these findings may lead to potential targets of
importance for the subgroup of patients with a PD IFX
treatment failure.
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